文献速递哮喘

本瑞利珠单抗治疗重度哮喘增强应答的预测因素:SIROCCO和CALIMA研究汇总分析

Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
PubMed 文献 · Lancet Respir Med · 2017-09-11

该汇总分析纳入SIROCCO和CALIMA两项随机双盲安慰剂对照3期研究,共2295例重度未控制哮喘患者,评估不同基线血嗜酸性粒细胞阈值和急性发作史对Benral利珠单抗疗效的影响。结果显示,随着基线血嗜酸性粒细胞阈值升高和既往急性发作次数增多,Benral利珠单抗降低年急性发作率(AER)的幅度增大,尤其在高嗜酸性粒细胞阈值合并频繁急性发作史的患者中改善更明显。

要点

  • Benral利珠单抗每4周或每8周方案均显著降低重度哮喘年急性发作率,且疗效随基线血嗜酸性粒细胞计数升高而增强。
  • 既往急性发作次数越多,Benral利珠单抗带来的AER改善越明显,高嗜酸性粒细胞阈值合并频繁发作史者获益最大。
  • 结果有助于临床医生决定是否使用Benral利珠单抗治疗重度未控制嗜酸性哮喘。

核心结论

  • Benral利珠单抗降低重度未控制哮喘年急性发作率的疗效随基线血嗜酸性粒细胞阈值升高和既往急性发作次数增多而增强。

研究设计与样本

  • 本研究为SIROCCO(NCT01928771)和CALIMA(NCT01914757)两项随机双盲安慰剂对照3期研究的汇总分析。
  • 共纳入2295例重度未控制哮喘患者,随机1:1:1接受Benral利珠单抗30mg每4周、每8周(前三次每4周)或安慰剂每4周皮下注射。
  • 主要终点为年急性发作率(AER)比值,按基线嗜酸性粒细胞计数(≥0、≥150、≥300或≥450 cells/μL)和入组前一年急性发作次数(2次 vs 3次及以上)分析,采用意向性治疗原则。

主要发现

  • 在每4周和每8周Benral利珠单抗组中,随着血嗜酸性粒细胞阈值升高和既往急性发作史增多,AER降低幅度增大。
  • 高血嗜酸性粒细胞阈值合并更频繁急性发作史的患者,Benral利珠单抗相比安慰剂对AER的改善更明显。

临床怎么用

  • 临床医生可依据基线血嗜酸性粒细胞计数和既往急性发作史,评估重度未控制哮喘患者使用Benral利珠单抗的预期获益。
  • 基线血嗜酸性粒细胞计数较高且既往急性发作频繁的患者,可能从Benral利珠单抗治疗中获得更大的AER改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor α monoclonal antibody that has been shown to significantly reduce asthma exacerbations and improve lung function for patients with severe, uncontrolled asthma. We further explored the efficacy of benralizumab for patients with different baseline blood eosinophil thresholds and exacerbation histories. METHODS: This study is a pooled analysis of the results from the randomised, double-blind, placebo-controlled SIROCCO (NCT01928771) and CALIMA (NCT01914757) phase 3 studies. In these studies, patients with severe, uncontrolled asthma were randomly assigned (1:1:1) to receive subcutaneous benralizumab 30 mg, either every 4 weeks or every 8 weeks (with first three doses given every 4 weeks), or placebo every 4 weeks. The primary endpoint was annual exacerbation rate (AER) ratio versus placebo, analysed by baseline eosinophil counts (≥0, ≥150, ≥300, or ≥450 cells per μL) and by number of exacerbations (two vs three or more) during the year before enrolment. The analyses were done in accordance with the intention-to-treat principle. FINDINGS: Of 2295 patients, 756 received benralizumab every 4 weeks, 762 received benralizumab every 8 weeks, and 777 patients received placebo. AER among patients with baseline blood eosinophil counts of at least 0 cells per μL was 1·16 (95% CI 1·05-1·28) in patients who received placebo versus 0·75 (0·66-0·84) in patients who received benralizumab every 8 weeks (rate ratio 0·64, 0·55-0·75; p<0·0001). In patients who received benralizumab every 4 weeks who had eosinophil counts of 0 or more cells per μL, AER was 0·73 (0·65-0·82); rate ratio versus placebo was 0·63 (0·54-0·74; p<0·0001). The extent to which exacerbation rates were reduced increased with increasing blood eosinophil thresholds and with greater exacerbation history in patients in the 4-weekly and 8-weekly benralizumab groups. Greater improvements in AER were seen with benralizumab compared with placebo for patients with a combination of high blood eosinophil thresholds and a history of more frequent exacerbations. INTERPRETATION: These results will help to guide clinicians when they are deciding whether to use benralizumab to treat patients with severe, uncontrolled, eosinophilic asthma. FUNDING: AstraZeneca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med. 2017. PMID: 28919200. doi:10.1016/S2213-2600(17)30344-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。